دورية أكاديمية
Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
| العنوان: | Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. |
|---|---|
| المؤلفون: | Michielsens CAJ; Department of Rheumatology, Sint Maartenskliniek Nijmegen.; Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen, the Netherlands., den Broeder N; Department of Rheumatology, Sint Maartenskliniek Nijmegen., Mulder MLM; Department of Rheumatology, Sint Maartenskliniek Nijmegen.; Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen, the Netherlands., van den Hoogen FHJ; Department of Rheumatology, Sint Maartenskliniek Nijmegen.; Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen, the Netherlands., Verhoef LM; Department of Rheumatology, Sint Maartenskliniek Nijmegen., den Broeder AA; Department of Rheumatology, Sint Maartenskliniek Nijmegen.; Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen, the Netherlands. |
| المصدر: | Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2022 May 30; Vol. 61 (6), pp. 2307-2315. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, UK : Avenel, N.J. : Oxford University Press ; Distributed by Mercury International, c1999- |
| مواضيع طبية MeSH: | Antirheumatic Agents*/therapeutic use , Arthritis, Psoriatic*/drug therapy , Axial Spondyloarthritis* , Spondylarthritis*/drug therapy , Spondylitis, Ankylosing*/drug therapy, C-Reactive Protein ; Humans ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor-alpha |
| مستخلص: | Objectives: We investigated the effect of disease activity-guided dose optimization (DAGDO) of TNF inhibitor (TNFi) on disease activity and TNFi dose in PsA and axial spondyloarthritis (axSpA) patients with low disease activity (LDA). Methods: A retrospective cohort study was conducted in PsA and axSpA patients doing well on TNFi and eligible for TNFi DAGDO. Three different treatment periods were defined: (i) full dose continuation period, (ii) TNFi DAGDO period, and (iii) period with stable TNFi dose after DAGDO. A mixed-model analysis was used to estimate mean Disease Activity Score 28-joint count CRP (DAS28-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) during these periods, and a mean percentage of the daily defined dose (%DDD) was calculated as secondary outcome. Results: Three hundred and twenty-four patients (153 PsA and 171 axSpA) were included, with a mean of 6.5 DAS28-CRP and 6.4 BASDAI measurements and a median follow-up duration of 46 and 44 months, respectively. A corrected difference of 0.06 (95% CI: -0.09, 0.21) in mean DAS28-CRP was found for the TNFi DAGDO period and 0.03 (95% CI: -0.14, 0.20) for the period with stable TNFi dose, compared with full dose continuation period. Differences for BASDAI were 0.03 (95% CI: -0.21, 0.27) and 0.05 (95% CI: -0.24, 0.34), respectively. The mean %DDD for the three treatment periods was for PsA 108%, 62% and 78%, and for axSpA 108%, 62% and 72%, respectively. Conclusion: DAGDO of TNFi reduces drug exposure and has no negative effects on disease activity in PsA and axSpA patients compared with full dose continuation. (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.) |
| References: | Trials. 2020 Jan 15;21(1):90. (PMID: 31941544) Lancet. 2018 Jul 14;392(10142):134-144. (PMID: 29961640) Arthritis Res Ther. 2020 Apr 29;22(1):97. (PMID: 32349791) Arthritis Rheumatol. 2018 Jan;70(1):60-68. (PMID: 29045077) Rheumatology (Oxford). 2016 Jul;55(7):1188-94. (PMID: 26998860) Ann Rheum Dis. 2021 Nov;80(11):1436-1444. (PMID: 33958325) Int J Immunopathol Pharmacol. 2013 Jul-Sep;26(3):833-8. (PMID: 24067486) Clin Rheumatol. 2018 Jun;37(6):1625-1632. (PMID: 29667099) Drugs. 2018 Nov;78(16):1705-1715. (PMID: 30341684) Arthritis Care Res (Hoboken). 2021 Jun;73(6):861-872. (PMID: 32166872) Ann Rheum Dis. 2015 Jun;74(6):1132-7. (PMID: 25143522) Ann Rheum Dis. 2020 Jun;79(6):685-699. (PMID: 31969328) Ann Rheum Dis. 2016 Mar;75(3):499-510. (PMID: 26644232) J Clin Rheumatol. 2018 Apr;24(3):127-131. (PMID: 29293113) BMJ Open. 2019 Jul 9;9(7):e028517. (PMID: 31292181) Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. (PMID: 31436036) Musculoskeletal Care. 2019 Mar;17(1):63-71. (PMID: 30398699) Ann Rheum Dis. 2013 Nov;72(11):1800-5. (PMID: 23178206) Arthritis Rheumatol. 2016 Feb;68(2):282-98. (PMID: 26401991) Cochrane Database Syst Rev. 2019 May 24;5:CD010455. (PMID: 31125448) Rheumatol Ther. 2017 Jun;4(1):1-24. (PMID: 28255897) BMJ. 2015 Apr 09;350:h1389. (PMID: 25858265) Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. (PMID: 27924643) Lancet. 2002 Apr 6;359(9313):1187-93. (PMID: 11955536) Arthritis Res Ther. 2019 Jan 8;21(1):11. (PMID: 30621746) Arthritis Rheumatol. 2021 Sep;73(9):1663-1672. (PMID: 33682378) Ann Rheum Dis. 2015 Apr;74(4):655-60. (PMID: 24336010) Ann Rheum Dis. 2016 Jun;75(6):991-6. (PMID: 26847821) RMD Open. 2017 Jan 16;3(1):e000395. (PMID: 28123783) Ann Rheum Dis. 2020 Jul;79(7):920-928. (PMID: 32381562) Lancet. 2015 Dec 19;386(10012):2489-98. (PMID: 26433318) Lancet. 2015 Jul 18;386(9990):258-65. (PMID: 25975452) Biologics. 2013;7:1-6. (PMID: 23319853) Arthritis Rheum. 2012 Oct;64(10):3150-5. (PMID: 22576997) J Rheumatol. 2013 Apr;40(4):379-85. (PMID: 23457377) Arthritis Rheumatol. 2017 Feb;69(2):301-308. (PMID: 27696778) Ann Rheum Dis. 2020 Jun;79(6):700-712. (PMID: 32434812) J Rheumatol. 2015 Jul;42(7):1177-85. (PMID: 26034151) Ann Rheum Dis. 2017 Jun;76(6):978-991. (PMID: 28087505) |
| فهرسة مساهمة: | Keywords: TNF inhibitors; axial spondyloarthritis; discontinuation; disease activity-guided; dose optimization; dose reduction; psoriatic arthritis; spacing; tapering; withdrawal |
| المشرفين على المادة: | 0 (Antirheumatic Agents) 0 (Tumor Necrosis Factor Inhibitors) 0 (Tumor Necrosis Factor-alpha) 9007-41-4 (C-Reactive Protein) |
| تواريخ الأحداث: | Date Created: 20211002 Date Completed: 20220602 Latest Revision: 20220716 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9157113 |
| DOI: | 10.1093/rheumatology/keab741 |
| PMID: | 34599803 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!